IPO - Profile


We are an innovative biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with significant unmet medical need. We have created a comprehensive allogeneic cell therapy platform that includes industry-leading induced pluripotent stem cells, or iPSCs, differentiation know-how to generate immune effector cells from iPSCs, or iPSC-derived cells, clustered regularly interspaced short palindromic repeats, or CRISPR, mediated precision gene editing that allows us to incorporate multiple transgenes and remove target genes intended to optimize cell product performance, sophisticated protein More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$20.00 10,600,000 Positive High 22.95%

Offering Team

  • Legal counsel
  • Davis Polk & Wardwell LLP
  • Auditors
  • Ernst & Young LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 17 Jun, 2021

Offer 18 Jun, 2021

Look Ahead

Lock Up Expiry Dec 18, 2021

IPO Terms

Offer Price $20.00
Offer Size 10M

Market Sentiments

Stock Price